MX371328B - Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion. - Google Patents

Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.

Info

Publication number
MX371328B
MX371328B MX2016002539A MX2016002539A MX371328B MX 371328 B MX371328 B MX 371328B MX 2016002539 A MX2016002539 A MX 2016002539A MX 2016002539 A MX2016002539 A MX 2016002539A MX 371328 B MX371328 B MX 371328B
Authority
MX
Mexico
Prior art keywords
fab
present
poly
serum albumin
effector fusion
Prior art date
Application number
MX2016002539A
Other languages
English (en)
Other versions
MX2016002539A (es
Inventor
Sanghoon Cha
Original Assignee
Aprilbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co Ltd filed Critical Aprilbio Co Ltd
Publication of MX2016002539A publication Critical patent/MX2016002539A/es
Publication of MX371328B publication Critical patent/MX371328B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al fragmento (Fab) de unión a antígeno y proteína de fusión o (poli) péptido efectores de Fab que lo comprenden. El Fab de la presente invención específicamente se une a albúmina de suero y por lo tanto tiene una vida media in vivo prolongada. El Fab de la presente invención se caracteriza por no tener residuos de cisteína que son responsables del enlace de disulfuro intercadena en el dominio CH1 y el dominio CKL también. La proteína de fusión o (poli) péptido efectores de Fab de la presente invención pueden producirse en periplasma de E. coli con alto rendimiento, y tiene una vida media in vivo aumentada. Adicionalmente, la presente invención provee la cepa E. coli que produce varias clases de proteínas de fusión o (poli) péptidos efectores de Fab, y una composición farmacéutica que comprende las proteínas de fusión o (poli)péptidos efectores de Fab.
MX2016002539A 2013-08-30 2014-08-29 Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion. MX371328B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Publications (2)

Publication Number Publication Date
MX2016002539A MX2016002539A (es) 2016-10-13
MX371328B true MX371328B (es) 2020-01-27

Family

ID=52586989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002539A MX371328B (es) 2013-08-30 2014-08-29 Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.

Country Status (17)

Country Link
US (2) US9879077B2 (es)
EP (2) EP3632930A1 (es)
JP (2) JP6422977B2 (es)
KR (2) KR101576561B1 (es)
CN (1) CN105899532B (es)
AU (1) AU2014312456B2 (es)
BR (1) BR112016004355A2 (es)
CA (1) CA2922618C (es)
DK (1) DK3039038T3 (es)
ES (1) ES2866848T3 (es)
HK (1) HK1223107A1 (es)
MX (1) MX371328B (es)
PH (1) PH12016500403A1 (es)
PL (1) PL3039038T3 (es)
RU (1) RU2661087C2 (es)
UA (1) UA117493C2 (es)
WO (1) WO2015030539A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CA3102036A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
WO2023242251A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Follistatin-fc fusion proteins
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
MXPA06014031A (es) * 2004-06-01 2007-10-08 Domantis Ltd Anticuerpos de fusion biespecificos con vida media de serica mejorada.
WO2007011363A2 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
CN101111522A (zh) * 2004-12-02 2008-01-23 杜门蒂斯有限公司 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
CA2596925C (en) * 2005-02-08 2017-07-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for improving expression level and stability of antibody
EP2160405A2 (en) * 2007-06-08 2010-03-10 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
EP2195341B1 (en) * 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
PL2288715T3 (pl) * 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
EA201100527A1 (ru) * 2008-09-26 2011-10-31 Юсб Фарма С.А. Биологические продукты
ES2688621T3 (es) * 2008-12-05 2018-11-05 Glaxo Group Limited Métodos para seleccionar polipéptidos resistentes a proteasa
JP6086528B2 (ja) * 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2776466B1 (en) * 2011-11-11 2017-08-23 UCB Biopharma SPRL Albumin binding antibodies and binding fragments thereof

Also Published As

Publication number Publication date
HK1223107A1 (zh) 2017-07-21
DK3039038T3 (da) 2021-02-08
EP3039038A4 (en) 2017-07-05
KR101576561B1 (ko) 2015-12-10
US9879077B2 (en) 2018-01-30
AU2014312456B2 (en) 2017-07-06
KR20150118565A (ko) 2015-10-22
AU2014312456A8 (en) 2016-03-17
PL3039038T3 (pl) 2021-04-19
CN105899532B (zh) 2021-10-08
AU2014312456A1 (en) 2016-03-03
EP3039038B1 (en) 2020-11-25
UA117493C2 (uk) 2018-08-10
WO2015030539A1 (en) 2015-03-05
JP6800180B2 (ja) 2020-12-16
BR112016004355A2 (pt) 2017-10-17
US10618953B2 (en) 2020-04-14
PH12016500403A1 (en) 2016-05-16
US20180030127A1 (en) 2018-02-01
JP6422977B2 (ja) 2018-11-14
US20160376350A1 (en) 2016-12-29
JP2018172391A (ja) 2018-11-08
CA2922618C (en) 2020-04-28
EP3039038A1 (en) 2016-07-06
ES2866848T3 (es) 2021-10-19
KR20150026997A (ko) 2015-03-11
EP3632930A1 (en) 2020-04-08
RU2661087C2 (ru) 2018-07-11
CN105899532A (zh) 2016-08-24
MX2016002539A (es) 2016-10-13
RU2016105586A (ru) 2017-10-04
JP2016528922A (ja) 2016-09-23
CA2922618A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
EA201591700A1 (ru) Гибридные белки апелина и их применение
MX2014005108A (es) Constructos de polipeptidos y sus usos.
EP3929217A3 (en) Specific sites for modifying antibodies to make immunoconjugates
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
SG10201805039UA (en) Protease resistant peptides
EA201790946A8 (ru) Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
WO2014152831A3 (en) Targeting peptides and uses thereof
NZ744289A (en) Composition containing amino acids
PL410410A1 (pl) Sposób otrzymywania rekombinowanego białka z prekursora
WO2012136792A3 (en) Cck compositions
AU2016274890A8 (en) Immunoglobulin fusion proteins and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration